# GT Biopharma, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/GT Biopharma, Inc.). ## Overview GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing immune-oncology therapies built on its proprietary TriKE® and Dual Targeting TriKE® platforms. Its programs are designed to harness a patient’s natural killer cells to attack cancer, but the company remains pre-commercial and dependent on financing to fund development. ## Products & services • TriKE® immune-oncology therapeutics • Dual Targeting TriKE® platforms • NK cell-engaging cancer therapies • Clinical-stage drug development programs - **TriKE® platform therapeutics** (70%) — Multi-specific biologic drug candidates designed to activate natural killer cells against cancer. - **Dual Targeting TriKE® therapeutics** (20%) — Next-generation platform programs that target two cancer-related antigens while engaging NK cells. - **Research and development services** (10%) — Internal discovery, translational work, and clinical development activities supporting the pipeline. - TriKE® multi-specific immune-oncology therapeutics - Dual Targeting TriKE® platform candidates - NK cell-engaging cancer therapies - Preclinical and clinical development programs - Potential future commercialization of oncology biologics ## Customers GT Biopharma does not sell a commercial product base today; its primary stakeholders are clinical investigators, research collaborators, regulators, and future oncology treatment providers. If approved, its therapies would be used by hospitals, cancer centers, and physicians treating patients with difficult-to-treat malignancies. - **Clinical and research collaborators** (primary) — Academic and clinical partners that support translational research, trial execution, and data generation for the pipeline. - **Regulatory authorities** (primary) — FDA and comparable agencies that review safety, efficacy, manufacturing, and labeling before commercialization. - **Future oncology treatment providers** (secondary) — Hospitals, cancer centers, and oncologists that would prescribe or administer approved therapies. - **Cancer patients** (secondary) — Patients with malignancies that may be eligible for NK-cell engaging immuno-oncology treatments. - Clinical investigators and research partners advancing trials - Regulators reviewing IND and future marketing applications - Hospitals and cancer centers as future treatment sites - Oncologists seeking NK-cell based immunotherapy options - Patients with cancers targeted by the company’s pipeline ## Geography The company is headquartered in the United States and operates as a U.S.-based clinical-stage biotech. The filings provided do not disclose meaningful country-by-country revenue, which is consistent with a development-stage company that has not yet built a commercial sales footprint. - Headquartered in the United States - No disclosed country revenue mix in the excerpts - Development work is centered on U.S. regulatory pathways - Future commercialization would likely depend on U.S. and global approvals ## Strategy GT Biopharma’s strategy is centered on advancing its TriKE® and Dual Targeting TriKE® platforms through development and toward regulatory approval. The company’s near-term priority is preserving liquidity and securing additional financing so it can continue clinical and preclinical work without interruption. - **Secure additional financing** (short-term) — The company disclosed substantial doubt about its ability to continue as a going concern without new capital. - **Advance clinical-stage immune-oncology programs** (medium-term) — Pipeline progress is the main value driver for a pre-commercial biotech. - **Maintain and defend intellectual property** (medium-term) — Platform protection is critical to differentiation and future partnering or commercialization. - Advance TriKE® and Dual Targeting TriKE® pipeline candidates - Use NK-cell biology to differentiate from standard oncology approaches - Pursue regulatory milestones needed for future commercialization - Raise capital to fund operations and avoid liquidity shortfalls - Protect intellectual property around platform technologies ## Risks The company faces classic clinical-stage biotech risks: financing dependence, regulatory uncertainty, and the possibility that its platform never reaches commercialization. Its disclosures also highlight competition from better-capitalized biotech and pharmaceutical companies, plus operational risks tied to cybersecurity, supply chain, and FDA compliance. - **Going concern and liquidity shortfall** [critical] — Management stated existing cash may not fund operations for one year without additional financing. - **Clinical development and regulatory failure** [high] — Product candidates may not demonstrate safety or efficacy, and approvals are uncertain. - **Competition from larger biotech and pharma companies** [high] — Competitors have greater capital, manufacturing, and regulatory resources. - **FDA and post-approval compliance** [medium] — Even approved products remain subject to manufacturing, labeling, and surveillance requirements. - **Intellectual property compromise** [high] — Loss or weakening of IP protection could reduce exclusivity and partnering value. - Going-concern risk if additional financing is not secured - Clinical and regulatory failure could stop pipeline value creation - Large competitors may reach approval faster or with better data - FDA post-approval compliance could trigger delays or penalties - IP disputes or compromise could weaken platform differentiation - Cybersecurity and operational disruptions could expose confidential data ## Accounting The most important accounting issue is going-concern assessment, because the company’s liquidity position and financing plans directly affect whether the financial statements are prepared on a going-concern basis. Investors should also watch fair value measurements for warrants and financing-related instruments, plus estimates around accrued expenses and deferred offering costs that can move materially in a small-cap biotech. - **Going concern** — Affects financial statement basis and investor assessment of solvency - **Warrant liability fair value** — Can create periodic non-cash gains or losses - **Deferred offering costs** — Affects current assets and equity transaction accounting - **Accrued expenses and accounts payable** — Can materially affect current liabilities and liquidity presentation - Going-concern disclosure reflects dependence on future financing - Fair value of warrant liability can create non-cash earnings volatility - Deferred offering costs affect equity financing presentation - Accrued expenses and payables are important in a cash-constrained biotech - Dissolution of subsidiaries affects consolidation and balance sheet structure --- *Last updated: 2026-04-28T20:10:48.365493+00:00*